REFERECES
  1. Afkarian, M., Sachs, M.C., Kestenbaum, B., Hirsch, I. B., Tuttle, K.R., Himmelfarb, J. … de Boer, I.H. (2013). Kidney disease and increased mortality risk in type 2 diabetes. Journal of American Society of Nephrology , 24, 302-308. doi:10.1681/ASN.2012070718
  2. Batlle, D., Wysocki, J., Soler, M.J. (2012). Angiotensin-converting enzyme 2: enhancing the degradation of angiotensin II as a potential therapy for diabetic nephropathy. Kidney International ., 81, 520-528. doi:10.1038/ki.2011.381
  3. Bellucci, P.N., González Bagnes, M.F., Di Girolamo, G., González, C.D. (2017). Potential Effects of Nonsteroidal Anti-Inflammatory Drugs in the Prevention and Treatment of Type 2 Diabetes Mellitus. Journal of Pharmacy Practice ., 30, 549-556. doi: 10.1177/0897190016649551
  4. Bilan, V.P., Salah, E.M., Bastacky, S., Jones, H.B., Mayers, R.M., Zinker, B., Poucher, S.M., Tofovic, S.P. (2011). Diabetic nephropathy and long-term treatment effects of rosiglitazone and enalapril in obese ZSF1 rats. Journal of Endocrinology , 210, 293-308. doi: 10.1530/JOE-11-0122
  5. Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., … Schnitzer, T.J. (2000). Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis, VIGOR Study Group. New England Journal of Medicine, 343, 1520–1528. doi: 10.1056/NEJM200011233432103
  6. Cases, A., Coll, E. (2005). Dyslipidemia and the progression of renal disease in chronic renal failure patients. Kidney International, 99, S87-S93. doi: 10.1111/j.1523-1755.2005.09916.x
  7. Catalá-López, F., Macías Saint-Gerons, D., González-Bermejo, D., Rosano, G.M.,…Hutton, B. (2016). Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses.PLoS Medicine , 13(3), e1001971. doi:10.1371/journal.pmed.1001971
  8. Chalikias, G., Tziakas, D. (2020). Angiotensin Receptor Neprilysin Inhibitors-2019 Update. Cardiovascular Drugs Ther apy, 10.1007/s10557-020-07015-8. doi:10.1007/s10557-020-07015-8
  9. Cheng, H., Wang, S., Jo, Y-I., Hao, C-M., Zhang, M., Fan, X., …Harris, R.C. (2007). Overexpression of cyclooxygenase-2 predisposes to podocyte injury. Journal of American Society of Nephrol ., 18, 551-559. doi: 10.1681/ASN.2006090990
  10. Cheng, H.F., Harris, R.C. (2004). Cyclooxygenases, the kidney, and hypertension. Hypertension, 43, 525-530. doi: 10.1161/01.HYP.0000116221.27079.ea
  11. Cho, J., Cooke, C.E., Proveaux, W. (2003). A retrospective review of the effect of COX-2 inhibitors on blood pressure change. American Journal of Therapy, 10, 311-317. doi:10.1097/00045391-200309000-00002
  12. Delanaye P, Scheen AJ. Preventing and treating kidney disease in patients with type 2 diabetes. Expert Opin Pharmacother . 2019;20(3):277-294. doi:10.1080/14656566.2018.1551362
  13. Dey, A., Maric, C., Kaesemeyer, W.H., Zaharis, C.Z., Stewart, J., Pollock, J.S., Imig, J.D. (2004). Rofecoxib decreases renal injury in obese Zucker rats. Clinical Sciences (Lond) , 107, 561–570. doi: 10.1042/CS20040125.
  14. EnayetAllah, A.E., Luria, A., Luo, B., Tsai, H-J., Sura, P., Hammock, B.D., Grant, D.F. (2008). Opposite Regulation of Cholesterol Levels by the Phosphatase and Hydrolase Domains of Soluble Epoxide Hydrolase.Journal of Biological Chemistry , 283, 36592-36598. doi: 10.1074/jbc.M806315200
  15. Ferro, C.L., Mark, P.B., Kanbay, M., Sarafidis, P., Heine, G.H., Rossignol, P.,… Zoccali, C. (2018). Lipid management in patients with chronic kidney disease Nature Review of Nephrology , 14, 727-749. doi: 10.1038/s41581-018-0072-9
  16. Fujihara, C.K., Antunes, G.R., Mattar, A.L., Andreoli, N., Malheiros D.M.A.C., … Zatz, R. (2003). Cyclooxygenase-2 (COX-2) inhibition limits abnormal COX-2 expression and progressive injury in the remnant kidney. Kidney International , 64, 2172-2181. doi: 10.1046/j.1523-1755.2003.00319.x
  17. Furman, D., Campisi, J., Verdin, E., Carrera-Bastos, P., Targ, S., …Slavich, G.M. (2019). Chronic inflammation in the etiology of disease across the life span. Nature Medicine , 25, 1822-1832. doi: 10.1038/s41591-019-0675-0
  18. Gartung, A., Yang, J., Sukhatme, V.P.,Bielenberg, D.R.,…Panigrahy, D. (2019). Suppression of chemotherapy-induced cytokine/lipid mediator surge and ovarian cancer by a dual COX-2/sEH inhibitor. Proceedings of National Academy of Sciences USA , 116, 1698-1703. doi:10.1073/pnas.1803999116
  19. Gassler, N., Elger, M., Kränzlin, B., Kriz, W., Gretz, N., …Hartmann, I. (2001). Podocyte injury underlies the progression of focal segmental glomerulosclerosis in the fa/fa Zucker rat, Kidney International, 60, 106-116. doi: 10.1046/j.1523-1755.2001.00777.x
  20. Grosser, T., Fries, S., FitzGerald, G.A. (2006). Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. Journal of Clinical Investigation, 116, 4-15. doi:10.1172/JCI27291
  21. Grundy, S.M. (2006). Drug Therapy of the Metabolic Syndrome: Minimizing the Emerging Crisis in Polypharmacy. Nature Review of Drug Discovery, 5, 295-309. doi: 10.1038/nrd2005
  22. Harris, R.C. (2008). An update on cyclooxygenase-2 expression and metabolites in the kidney. Current Opinion of Nephrology and Hypertension , 17, 64-69. doi: 10.1097/MNH.0b013e3282f1bb7d
  23. Harris, T.R., Bettaieb, A., Kodani, S., Dong, H., Myers, R., … Hammock, B.D. (2015) Inhibition of soluble epoxide hydrolase attenuates hepatic fibrosis and endoplasmic reticulum stress induced by carbon tetrachloride in mice. Toxicology and Applied Pharmacology, 286,102-111. doi: 10.1016/j.taap.2015.03.022
  24. Homer, B.L., Dower, K. (2018). 41-Week Study of Progressive Diabetic Nephropathy in the ZSF1 fa/faCP Rat Model. Toxicology and Pathology , 46, 976-977. doi: 10.1177/0192623318803278
  25. Horrillo, R., Planagumà, A., González-Périz, A., Ferré, N.,…Clària, J. (2007). Comparative protection against liver inflammation and fibrosis by a selective cyclooxygenase-2 inhibitor and a nonredox-type 5-lipoxygenase inhibitor. Journal of Pharmacology and Experimental Therapeutics, 323, 778-786. doi:10.1124/jpet.107.128264
  26. Hotamisligil, G.S. (2006). Inflammation and metabolic disorders.Nature , 444, 860–867. doi: 10.1038/nature05485
  27. Hye Khan, M.A,. Hwang, S.H., Sharma, A., Corbett, J.A., …Imig, J.D. (2016). A dual COX-2/sEH inhibitor improves the metabolic profile and reduces kidney injury in Zucker diabetic fatty rat. Prostaglandins and Other Lipid Mediators , 125, 40-47. doi: 10.1016/j.prostaglandins.2016.07.003
  28. Hye Khan, M.A., Kolb, L., Skibba, M., Hartmann, M., Blöcher, R.,… Imig, J.D. (2018). A novel dual PPAR-γ agonist/sEH inhibitor treats diabetic complications in a rat model of type 2 diabetes. Diabetologia , 61, 2235-2246. doi: 10.1007/s00125-018-4685-0
  29. Hye Khan, M.A., Schmidt, J., Stavniichuk, A., Imig, J.D., Merk, D. (2019). A dual farnesoid X receptor/soluble epoxide hydrolase modulator treats non-alcoholic steatohepatitis in mice. Biochemical Pharmacology , 166, 212-221. doi: 10.1016/j.bcp.2019.05.023
  30. Ilatovskaya, D.V., Palygin, O., Levchenko, V., Endres, B.T., Staruschenko, A. (2017). The Role of Angiotensin II in Glomerular Volume Dynamics and Podocyte Calcium Handling. Scientific Reports , 7, 299. doi: 10.1038/s41598-017-00406-2
  31. Imig, J.D.  Walsh, K.A., Hye Khan, M.A., Nagasawa, T., Cherian-Shaw, M., … Hammock, B.D. (2012) Soluble epoxide hydrolase inhibition and peroxisome proliferator activated receptor γ agonist improve vascular function and decrease renal injury in hypertensive obese rats. Experimental Biology and Medicine (Maywood) , 237, 1402-1412. doi: 10.1258/ebm.2012.012225
  32. Imig, J.D. (2018). Prospective for cytochrome P450 epoxygenase cardiovascular and renal therapeutics. Pharmacology and Therapeutics, 192, 1-19. doi: 10.1016/j.pharmthera.2018.06.015
  33. Imig, J.D., Zhao, X., Capdevila, J.H., Morisseau, C., Hammock, B.D. (2002). Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension . 39(2002) 690-694. doi: 10.1161/hy0202.103788
  34. Imig, J.D., Zhao, X., Zaharis, C.Z., Olearczyk, J.J., Pollock, D.M., … Hammock, B.D. (2005). An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension, 46, 975-981
  35. Isomaa, B., Almgren, P., Tuomi, T., Forsén, B., Lahti, K.,… Groop, L. (2001). Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care , 24, 683-689. doi: 10.2337/diacare.24.4.683
  36. Kim, J., Yoon, S.P., Toews, ML, Imig, J.D., Hwang, S.H., …Padanilam, B. (2015). Pharmacological inhibition of soluble epoxide hydrolase prevents renal interstitial fibrogenesis in obstructive nephropathy. American Journal of Physiology Renal Physiology, 308, F131-F139. doi: 10.1152/ajprenal.00531.2014
  37. Liu, Y., Dang, H., Li, D., Pang, W., Hammock, B.D., Zhu, Y. (2012). Inhibition of Soluble Epoxide Hydrolase Attenuates High-Fat-Diet–Induced Hepatic Steatosis by Reduced Systemic Inflammatory Status in Mice. PLoS ONE , 7, e39165. doi: 10.1371/journal.pone.0039165
  38. Lorthioir, A., Guerrot, D., Joannides, R., Bellien, J. (2012). Diabetic CVD–soluble epoxide hydrolase as a target. Cardiovascular & Hematological Agents in Medicinal Chemistry, 10, 212-222. doi: 10.2174/187152512802651042
  39. Ma, S., Zhu, X-Y., Eirin, A., Woollard, J.R. Jordan, K.L.,…Lerman, L.O. (2016) Perirenal fat promotes renal arterial endothelial dysfunction in obese swine 508 through tumor necrosis factor-alpha. Journal of Urolpgy, 195, 1152–1259. doi: 10.1016/j.juro.2015.08.105
  40. Manhiani, M., Quigley, J.E., Knight, S.F., Tasoobshirazi, S.T., Moore, T., … Imig, J.D. (2009). Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension. American Journal of Physiology Renal Physiology,297, F740-F748. doi: 10.1152/ajprenal.00098.2009
  41. Nandakishore R., Yalavarthi, P.R., Kiran, Y.R., Rajapranathi, M. (2014). Selective cyclooxygenase inhibitors: current status.Current Drug Discovery and Technology , 11, 127-132. doi:10.2174/1570163811666140127123717
  42. Nasrallah, R., Hassouneh, R., Hébert, R.L. (2016). PGE2, Kidney Disease, and Cardiovascular Risk: Beyond Hypertension and Diabetes. Journal of American Society of Nephrology, 27, 666-676. doi: 10.1681/ASN.2015050528
  43. Neckář. J., Kopkan. L., Husková, Z., Kolář, F., Papoušek, F.,… Červenka, L. (2012). Inhibition of soluble epoxide hydrolase by cis-4-[4-(3-adamantan-1-ylureido)cyclohexyl-oxy]benzoic acid exhibits antihypertensive and cardioprotective actions in transgenic rats with angiotensin II-dependent hypertension. Clinical Science (London), 122, 513-525. doi: 10.1042/CS20110622
  44. Patti, A.M., Rizvi, A.A., Giglio, R.V., Stoian, A.P., Ligi, D., Mannello, F. (2020). Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes. Journal of Clinical Medicine, 9, 912. doi:10.3390/jcm9040912
  45. PTUPB ameliorates high-fat diet-induced non-alcoholic fatty liver disease via inhibiting NLRP3 inflammasome activation in mice. Biochemical and Biophysical Research Communications , 523, 1020-1026. doi: 10.1016/j.bbrc.2019.12.131
  46. Ritz, E., Tarng, D.C. (2001). Renal disease in type 2 diabetes. Nephrology Dialysis and Transplantation, 5, 11-18. doi: 10.1093/ndt/16.suppl_5.11
  47. Roche, C., Guerrot, D., Harouki, N., Duflot, T., Besnier, M.,…Bellien, J. (2015). Impact of soluble epoxide hydrolase inhibition on early kidney damage in hyperglycemic overweight mice. Prostaglandins and Other Lipid Mediators, 120, 148-154. doi: 10.1016/j.prostaglandins.2015.04.011
  48. Rosenthal, T., Erlich, Y., Rosenmann, E., Grossman, E., Cohen, A. (1995). Enalapril improves glucose tolerance in two rat models: a new hypertensive diabetic strain and a fructose-induced hyperinsulinaemic rat. Clinical and Experimental Pharmacology and Physiology,1995;22(1):S353-S354. doi: 10.1111/j.1440-1681.1995.tb02951.x
  49. Safaeian, L., Hajhashemi, V., Ajoodanian, M. (2018) The effect of celecoxib on blood pressure and plasma oxidant/antioxidant status in co-administration with glucocorticoid in rat. Biomed Pharmacother , 108, 1804-1808. doi:10.1016/j.biopha.2018.10.047
  50. Saran, R., Robinson, B., Abbott, K.C., Bragg-Gresham, J., Xiaoying Chen, X.,… Shahinian, V. (2020). US Renal Data System 2019 Annual Data Report: Epidemiology of Kidney Disease in the United States. American Journal of Kidney Disease, 75, A6-A7. doi: 10.1053/j.ajkd.2019.09.003
  51. Su, Z., Widomski, D., Nikkel, A., Leys, L…,. McGaraughty, S. (2018). Losartan improves renal function and pathology in obese ZSF-1 rats. Journal of Basic and Clinical Physiologyl Pharmacoogy,9(3), 281-290. doi:10.1515/jbcpp-2017-0157
  52. Toth-Manikowski, S., Atta, M.G. (2015). Diabetic Kidney Disease: Pathophysiology and Therapeutic Targets. Journal of Diabetes Research, . 2015, 697010. doi: 10.1155/2015/697010
  53. Vuorinen-Markkola, H., Yki-Järvinen, H. (1995). Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus. Metabolism , 44, 85-89. doi: 10.1016/0026-0495(95)90293-7
  54. Warren, A.M., Knudsen, S.T., Cooper, M.E. (2019). Diabetic nephropathy: an insight into molecular mechanisms and emerging therapies. Expert Opinion in Therapeutic Targets , 23, 579-591.  doi: 10.1080/14728222.2019.1624721
  55. Williams, J.M., Sharma, M., Anjaiahh, S., Falck, J.R., Roman, R.J. (2007). Role of endogenous CYP450 metabolites of arachidonic acid in maintaining the glomerular protein permeability barrier. American Journal of Physiology and Renal Physiology,293, F501-F505. doi: 10.1152/ajprenal.00131.2007
  56. Xie X, Atkins E, Lv J, Bennett, A.,…Rodgers, A. (2016). Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet , 387, 435-443. doi:10.1016/S0140-6736(15)00805-3
  57. Younossi, Z.M., Henry, L. (2019). The Impact of Obesity and Type 2 Diabetes on Chronic Liver Disease. American Journal of Gastroenterology, 114, 1714-1715. doi: 10.14309/ajg.0000000000000433
  58. Zhang, X., Lerman, L.O. (2016). The metabolic syndrome and chronic kidney disease. Translational Research, 183, 14-25. doi: 10.1016/j.trsl.2016.12.004
  59. Zhang, Y.F., Sun, C.C., Duan, J.X., Yang, H.H.,…Guan, C.X. (2020). A COX-2/sEH dual inhibitor PTUPB ameliorates cecal ligation and puncture-induced sepsis in mice via anti-inflammation and anti-oxidative stress. Biomeddical Pharmacotherapy , 126, 109907. doi:10.1016/j.biopha.2020.109907
  60. Zhao, X., Dey, A., Romanko, O.P., Stepp, D.W., Wang, H.H., …Imig, J.D. (2005). Decreased epoxygenase and increased epoxide hydrolase expression in the mesenteric artery of obese Zucker rats.American Journal of Physiology Regulatory Integrative and Comparative Physiology , 288, R188-R196. doi: 10.1152/ajpregu.00018.2004